Related Experiment Videos
[Prosthetic valve endocarditis: complication following cardiac surgery]
Noboru Motomura1, Shinichi Takamoto
1Department of Cardiac Surgery, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Nihon Geka Gakkai Zasshi
|February 26, 2003
Summary
Prosthetic valve endocarditis (PVE) is a serious complication after valve replacement. Identifying causative organisms like Staphylococcus or Streptococcus is key for effective treatment and choosing between re-operation or allografts.
Area of Science:
- Cardiovascular Surgery
- Infectious Diseases
- Biomaterials
Context:
- Prosthetic valve endocarditis (PVE) is a rare but severe complication post-valve replacement surgery.
- Early PVE (<60 days) often involves Staphylococcus, linked to nosocomial or intraoperative infections.
- Late PVE (>1 year) resembles native valve endocarditis, with Streptococcus as a common cause.
Purpose:
- To highlight the critical importance of identifying the causative organism in prosthetic valve endocarditis (PVE).
- To discuss treatment strategies for PVE, including re-operation and the preference for cryopreserved aortic valve allografts.
- To explore alternative and future therapeutic approaches for PVE.
Summary:
- Effective PVE treatment hinges on accurate identification of the primary pathogen, differentiating between early (Staphylococcus) and late (Streptococcus) phases.
- Surgical intervention, including a second valve replacement, is indicated for uncontrollable infection or cardiac failure.
- Cryopreserved aortic valve allografts are the preferred option due to favorable biological characteristics, though availability is limited.
Impact:
- Understanding PVE's distinct phases and causative agents guides timely and appropriate clinical management.
- The study underscores the potential of allografts and advanced techniques like tissue engineering for improving PVE outcomes.
- Limited availability of allografts necessitates continued research into alternative prosthetic valve modifications and treatments.